Search

Displaying results 4701 - 4710 of 10000 in total
  1. Target

    Low affinity immunoglobulin gamma Fc region receptor III-A

    go.drugbank.com/bio_entities/BE0002097
    TargetHumans

    Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor III-ASynonyms: IgG Fc receptor III-A
  2. Drug

    Sitagliptin

    go.drugbank.com/drugs/DB01261
    ApprovedInvestigational

    Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256 … The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255].

    Mixtures: SITAGLIPTIN E METFORMINA GALENICUM, SITAGLIPTIN E METFORMINA GALENICUMCategories: Drugs Used in Diabetes, Cytochrome P-450 Substrates
  3. Drug

    Semaglutide

    go.drugbank.com/drugs/DB13928
    ApprovedInvestigational

    Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. … [L41335] On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports.

    Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsProducts: Wegovy® 1 mg/0.5 mL (1 mg/dose) Solution for injection in pre-filled pen, Ozempic® 1.34 mg/ml (1 mg/dose) Solution for injection in pre-filled pen
  4. Drug

    Colloidal oatmeal

    go.drugbank.com/drugs/DB11286
    ApprovedNutraceutical

    It is available in topical products as a skin soothing agent. … Colloidal oatmeal is a FDA-approved skin protectant that temporarily protects and helps relieve minor skin irritation and itching due to rashes, eczema, poison ivy, oak, sumac, or insect bites.

    Mixtures: Pediadermics Eczema 3, 5% Oat Facial CleanserProducts: A Bit Hippy, TMC-A Hair Tonic
  5. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

    Categories: Immunoglobulin G, CTLA-4-directed Blocking AntibodyProducts: YERVOY®5 MG /ML SOLUCION INYECTABLE PARA INFUSION INTRAVENOSA, YERVOY 5 mg/ml concentrate for solution for infusion
  6. Drug

    Treprostinil

    go.drugbank.com/drugs/DB00374
    ApprovedInvestigational

    However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature. … [L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life.

    Categories: Prostaglandins I, Cytochrome P-450 SubstratesProducts: REMODULIN ® INYECCIÓN 1 MG/ML, TIMERAXONE®2.5 MG/ML
  7. Drug

    Hydralazine

    go.drugbank.com/drugs/DB01275
    ApprovedInvestigational

    [A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications. … Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.

    Synonyms: 6-Hydralazine, 1-HydrazinophthalazineInternational brands: Cesoline W, Cesoline Y
  8. Drug

    Esketamine

    go.drugbank.com/drugs/DB11823
    ApprovedInvestigational

    [L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications … Esketamine is the s-enantiomer of [Ketamine]. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use.

    Synonyms: (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone, L-ketamineInternational brands: Keta-S, Ketanest S
  9. Drug

    Ranolazine

    go.drugbank.com/drugs/DB00243
    ApprovedInvestigational

    [L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.

    Categories: MATE 1 Inhibitors, MATE 2 InhibitorsProducts: RANEXICOR ® 500, RANEXICOR ® 1000
  10. Drug

    Pentoxifylline

    go.drugbank.com/drugs/DB00806
    ApprovedInvestigational

    [A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated for … [A226410, A226415, A226455] More recently, PTX has been suggested as a possible treatment for COVID-19-induced pulmonary complications due to its ability to regulate the production of inflammatory cytokines

    International brands: An Ruo Ning, Ao Le NiMixtures: Betamethasone Dipropionate 0.05% / Minoxidil 5% / Niacinamide 2% / Pentoxifylline 0.5%